If you wish to place meeting details on this site and you are not a member of the BACR you must first create a new account at Login. Please note your event will be published following approval by the administrator
The mechanisms needed to ensure clinical proteomic discoveries are translated to the clinic are a major challenge, both in defining them and establishing them. The goal of this conference is to discuss the most effective ways in which discoveries such as novel biomarkers can be integrated with current clinical laboratory medicine for the benefit of the patient. Further information can be found at: https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=123
The next international symposium of the Cambridge Research Institute will take place on 19-20 March 2010.
The topic is “Unanswered Questions in Tumour Monitoring” with sessions in:
Each session consists of invited talks and one selected talk, and a 45 min panel discussion. As in previous years, we have a great list of speakers, further details can be found at the website: http://www.cambridgecancer.org.uk/seminars/symposium/programme?version=6
Registration fees are: £375 for full registration or £150 for non-residential registration.
We hope you may be able to join us and make this a successful meeting. To register: http://science.cancerresearchuk.org/groups/cri_symposium/registration/
Aim: This year’s meeting will particularly concentrate on the patterns of spread of common cancers and recent changes. It will also provide an overview of current and emerging applications of PET/CT in oncology. Objectives: The two day conference on PET/CT will bring together leading European experts in the field of PET/CT. It is anticipated that the participants will benefit from: • A comprehensive overview of the current and emerging applications of FDG PET/CT in oncology • An update on recent advances in PET/CT in oncology • Interactive presentation of cases to illustrate various pitfalls and highlight the strengths and limitations of FDG PET/CT in oncology • An opportunity to raise questions and discussions with leading practitioners in the field Contact: Ruth Threadgold Events Co-ordinator Royal Society of Medicine 1 Wimpole Street, London, W1G 0AE. Tel: (+44) (0) 20 7290 3942 Fax: (+44) (0) 20 7290 2989 Email: Radiology@rsm.ac.uk
Website: www.aicrconference2010.co.uk AICR, the Association for International Cancer Research would be delighted if you could join us in celebrating our 30th anniversary in 2010. We have arranged an international scientific conference entitled “Today’s Research – Tomorrow’s Therapies” to be held in the historic city of St Andrews, Fife, Scotland from 7 to 9 April 2010. The anniversary conference is a major gathering for scientists working to illustrate how development in basic research can feed through to translational studies and the important role of model systems in both areas of cancer research. Over the past 30 years, AICR has supported over 1,650 research projects in 32 countries and has spent in excess of £125m worldwide. AICR is the only cancer charity which funds research anywhere in the world, giving us a truly international perspective on progress in this area. Recognised worldwide as the ‘Home of Golf’, St Andrews is a charming and picturesque royal burgh; it is rich in history and still retains many important historical sites and preserves the mediaeval layout of its town centre. Located on Scotland’s east coast, St Andrews offers miles of unspoilt sandy beaches and is the perfect base from which to explore the wider Kingdom of Fife and the rest of Scotland. The conference will take place in the Fairmont St Andrews, nestled proudly amidst the rugged, coastal landscape of the North Sea, whilst commanding spectacular views of the bay's golden beaches and medieval St Andrews. We hope you will help us celebrate our 30th Anniversary in style and we look forward to seeing you in St Andrews!
The Drug Resistance Workshop 2010 will be held on Wed 12 May 2010 at the Hammersmith Conference Centre, Hammersmith Hospital, London. For more information about the meeting and a registration package please contact ernesto.yague@imperial.ac.uk Chemotherapy is still one of the major therapies used to treat cancer. Unfortunately, resistance to chemotherapeutic treatment remains the main cause of cancer mortality. Notable advances have been done in the last years to understand the basic mechanisms underlying drug resistance and its implications in the clinical practice. However, more work is needed not only to define the basic biology behind, but to design therapeutic strategies applicable in the clinic. The Drug Resistance Workshop is the only UK forum in which both clinicians and scientists can discuss topics related with cancer resistance to chemotherapy and is organized with a periodicity of between 2 to 3 years. The 2005 meeting was highlighted in a Meeting Report in the British Journal of Cancer (2005) 93,973-976.
Breast Cancer Research 2010 Conference
Achievements in breast cancer research is the theme of the Breast Cancer Research 2010 which takes place at the Royal Society in the heart of London on 18 May 2010. It is open to all researchers with an interest in breast cancer.
Breast Cancer Campaign’s key objectives are to build the talent pool in breast cancer research, encourage scientific innovation, engage in scientific and public dialogue and ensure research that translates into patient benefit continues.
The conference programme will reflect these goals; showcasing the wide reaching research funded by the charity and the abundance of talent in the wider breast cancer research field.
Campaign’s Scientific Organising Committee is pleased to announce two excellent keynote speakers who are both experts in their fields.
The programme will also include an extensive selection of abstract and the deadline for submissions is Friday 20th November. All abstracts from the conference will be published in the online open access journal Breast Cancer Research.
In line with Campaign’s aim of supporting young researchers at the beginning of their career, the charity will once again be awarding its Emerging Investigator Poster Prize to the scientist that most effectively communicates their research.
To find out more visit the conference website at www.bccconference.ukevents.org or e-mail the secretariat at campaign@hamptonmedical.com.
In this scientific meeting, we will focus on personalised medicine and its impact on the use of novel therapeutics. We will discuss the clinical impact of these developments and the importance of the laboratory and regulatory changes on this aim. Faculty Professor Garth Morgan, Consultant Haematologist Professor David Cunningham, Consultant in Medical Oncology Professor Martin Gore, Consultant, General Medicine Professor Ian Smith, Consultant, General Medicine Professor Stan Kaye, Professor of Medical Oncology Professor Ian Judson, Clinical Consultant Professor Paul Workman Dr Jorge Reis-Filho, Team Leader - Molecular Pathology Dr Christopher Lord, Senior Staff Scientist Dr Faith Davies, Consultant Haematologist Professor Richard Marais, Professor of Molecular Oncology Dr David Gonzalez-de-Castro, Clinical Scientist Dr Ian Chau, Consultant Medical Oncologist Dr Sanjay Popat, Consultant Medical Oncologist Dr James Larkin, Consultant Medical Oncologist Dr Johanna De Bono, Consultant Oncologist Dr Chris Nutting, Clinical Oncologist To register your free place please email: diane.forzani@icr.ac.uk Tel: 020 8 722 4130 Or in writing to: The Royal Marsden Hospital Haemato-Oncology Unit Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG
Synopsis This symposium will showcase exciting developments in cancer drug discovery, from both an academic and industrial perspective. Topics will range from the characterisation of potential new drug targets through to medicinal chemistry case studies and the identification of clinical drug candidates. A key feature of this event is to create an opportunity for interaction and discussion between scientists from academia and industry.
Programme Keynote lecture: chemistry of cancer therapeutics – past lessons and future prospects Dr Andrew Thomas (AstraZeneca) Quadruplex nucleic acids as functional elements and therapeutic targets Prof Shankar Balasubramanian (University of Cambridge) Discovery of orally active selective inhibitors of PLK1 Dr Joanne Pinder (Vertex) Sulfatase inhibitors: from concept to clinic Prof Barry Potter (University of Bath) Discovery of improved tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: nilotinib and beyond Dr Paul W. Manley (Novartis Institute of BioMedical Research - Basel) Oxygenases and oxygen sensing - new targets for cancer? Prof Christopher Schofield (University of Oxford) Quinones: synthesis and anticancer properties Prof Christopher Moody (University of Nottingham) closing remarks and wine mixer With thanks to our sponsors
Delegate Fees Please note fees include the 5% discount for making an online booking. GB£76........................BACR / RSC / SCI Member GB£19........................Student / Subsidised Member GB£100......................Non-Member Organising Committee Dr Steven Howard (Astex Therapeutics) Prof Keith Jones (Institute of Cancer Research, Sutton) Dr Tony Raynham (Cancer Research Technology) Dr Nat Monck (Cancer Research Technology) Dr Gordon Saxty (Astex Therapeutics) Dr Andrew Westwell (Cardiff University) For more information, please contact: Conference Team T: +44 (0)20 7598 1561 F: +44 (0)20 7235 7743 E: conferences@soci.org
The European Workshop on Cytogenetics and Molecular Genetics of Solid Tumors is one of the most relevant cancer research meetings in Europe. The workshop will take place at the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. During previous workshops we have witnessed the emergence of novel insights into the role of chromosomal abnormalities and gene mutations in the development of both hereditary and non-hereditary human solid tumors. Now we are moving into a new era in which comprehensive sequence-based information on vast numbers of tumors can be obtained. Such information will provide us with detailed perspectives on how individual tumors develop. Additionally, this information can be employed for the generation of novel diagnostic and prognostic markers and the design of novel therapeutic strategies.
PROGRAM
The invited speakers: Mike Stratton (UK), René Bernards (Netherlands), Ian Tomlinson (UK), Gilles Thomas (France), Jan Hoeijmakers (Netherlands), Bryan Young (UK), Larissa Savelyeva (Germany), Ileana Zucchi (Italy), Manon van Engeland (Netherlands), Stephan Beck (UK) and Henk Stunnenberg (Netherlands) are all leading, world-renowned scientists. They will present the latest findings on the cancer genome, the cancer methylome, the cancer fragilome and the cancer transcriptome. Click on www.ewcmst.org for more details about the scientific program.
REGISTRATION AND ABSTRACT SUBMISSION
The registration and abstract submission is open. Abstracts will be published in Cancer Genetics and Cytogenetics.
NIJMEGEN
Nijmegen, the oldest city in the Netherlands, is situated on a range of hills near the river Waal. The city has attracted people since its very foundation. The surrounding area features hills, woods and polders, creating a varied countryside offering a range of recreational opportunities to both citizens and tourists. The city is easily accessible by all means of transport.
WWW.EWCMST.ORG
Please visit the EWCMST website www.ewcmst.org for more details, registration and abstract submission.